Sorafenib

Sorafenib is marketed as NEXAVAR, an oral multikinase inhibitor indicated for unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and radioactive iodine-refractory differentiated thyroid carcinoma. The label describes inhibition of multiple intracellular and cell-surface kinases involved in tumor proliferation and angiogenesis. U.S. initial approval was in 2005.

Drug Class

Multikinase inhibitor

Approval Status

FDA approved (Initial U.S. Approval: 2005)

Mechanism of Action

Inhibits multiple intracellular and cell-surface kinases (including RAF, VEGFR, PDGFR, KIT, FLT-3, and RET), reducing tumor proliferation and angiogenesis.